Countable Labs introduced a single-molecule precision PCR platform designed to directly count nucleic acids rather than rely on statistical inference. In an Innovation Spotlight, CEO Giovanna Prout described how single-molecule counting targets two pain points in clinical and biomanufacturing measurements: rare event detection and run-to-run reproducibility. The company argues its approach improves confidence when measuring very low concentrations, including viral titer, vector copy number, residual DNA impurities in gene and cell therapy, and oncology markers such as ctDNA and minimal residual disease. For digital PCR users, reproducibility across sites can be limited by standard-curve and Poisson-correction approaches; Countable’s platform is positioned as a more threshold-ready measurement method where ambiguity can’t be tolerated. In translational pipelines, more reliable quantification can affect release testing, comparability studies, and biomarker-driven decision making—especially in regulatory-facing settings.